Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(166 productos)
- Bcr-Abl(117 productos)
- EGFR(551 productos)
- FAK(72 productos)
- FLT(88 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(176 productos)
- JAK(243 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(51 productos)
- VDA(2 productos)
- VEGFR(236 productos)
Mostrar 6 subcategorías más
Se han encontrado 2269 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BPC 157 (X acetate)
CAS:Body Protection Compound 157 (BPC 157) is a pentadecapeptide derived from BPC, identified in gastric juice, exhibiting diverse biological activities. At 2 µg/ml, BPC 157 enhances primary rat tendon fibroblast cell migration and F-actin formation. Furthermore, doses of 0.01 and 10 µg/kg, intraperitoneally (i.p.), mitigate paw swelling, bone erosion, and mononuclear cell infiltration in the joints of rats with rheumatoid arthritis induced by complete Freund's adjuvant (CFA). It also diminishes gastric ulcer size in rats caused by indomethacin, aspirin, or diclofenac at these doses. Additionally, BPC 157 reduces catalepsy duration and tremor severity in a mouse model of Parkinson's disease triggered by MPTP.Fórmula:C62H98N16O22XC2H4O2Forma y color:SolidPeso molecular:1419.54AG-825
CAS:AG-825（Tyrphostin C15） is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (TyrphostinFórmula:C19H15N3O3S2Pureza:99.52%Forma y color:Yellow SolidPeso molecular:397.47Ref: TM-T14138
1mg34,00€5mg66,00€10mg105,00€25mg222,00€50mg371,00€100mg597,00€500mg1.234,00€1mL*10mM (DMSO)73,00€Os30
Os30 is a potent fourth-generation EGFR inhibitor, specifically targeting the EGFRC797S-TK mutation with IC50 values of 18 nM for EGFRDel19/T790M/C797S TK and
Pureza:98%Forma y color:Odour SolidAST5902 (trimesylate)
CAS:AST5902 trimesylate is the primary metabolite of Alflutinib (AST2818) both in vivo and in vitro. It exhibits antitumor activity. Alflutinib functions as an EGFR inhibitor.Fórmula:C30H41F3N8O11S3Forma y color:SolidPeso molecular:842.884K882
K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.Fórmula:C18H16N2O2Forma y color:SolidPeso molecular:292.33MS9449
CAS:MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Fórmula:C60H76ClFN10O8SPureza:98%Forma y color:SolidPeso molecular:1151.82Multi-kinase-IN-4
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.Fórmula:C21H20ClFN2OSPureza:98%Forma y color:SolidPeso molecular:402.91PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97Self-assembling peptide pY1
Self-assembling peptide pY1, which aggregates around cancer cells, specifically targets the EGFR receptor. When co-cultured with Ovalbumin (OVA), pY1 effectively inhibits the endocytosis of OVA.Fórmula:C104H125N24O29PForma y color:SolidPeso molecular:2206.22IMPDH2-IN-4
IMPDH2-IN-4 (compound 2d) is a Mycophenolic acid analog and a selective IMPDH2 inhibitor with a Ki of 1.8 μM. It exhibits potent cytotoxic activity against osteosarcoma cancer cell lines. Additionally, IMPDH2-IN-4 demonstrates high affinity for VEGFR-2, CDK2, and IMPDH.Fórmula:C35H34O6SiForma y color:SolidPeso molecular:578.73FAK-IN-24
CAS:FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.Fórmula:C39H45Cl2F3N8O3Forma y color:SolidPeso molecular:801.728SNIPER(ABL)-044
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving aFórmula:C51H64F3N9O8SPureza:98%Forma y color:SolidPeso molecular:1020.17FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Fórmula:C29H35N7O5Forma y color:SolidPeso molecular:561.63hCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Fórmula:C21H17FN6O3SPureza:98%Forma y color:SolidPeso molecular:452.46DSPE-PEG2000-A7R
DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Forma y color:Odour SolidPKCε (85-92)
CAS:PKCε (85-92) (ψεRACK) is a peptide and selective PKCε activator, induces a pro-angiogenic response, promotes FGF-2 cytosolization, regulates VEGF activity.Fórmula:C39H54N10O14Pureza:98.71%Forma y color:SolidPeso molecular:886.91LC-SF-14
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.Fórmula:C44H50Cl3N13O5SForma y color:SolidPeso molecular:977.28442HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Fórmula:C60H69N17O11SForma y color:SolidPeso molecular:1236.36ARRY-380 (analog )
CAS:ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.Fórmula:C29H27N7O4SPureza:99.82%Forma y color:SolidPeso molecular:569.63Ref: TM-T2518
1mg34,00€2mg47,00€5mg71,00€10mg104,00€25mg170,00€50mg253,00€100mgA consultar1mL*10mM (DMSO)92,00€VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Fórmula:C29H27N9OPureza:98%Forma y color:SolidPeso molecular:517.58
